Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36

Vor Biopharma Inc. (NYSE:VOR) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $11.36.

A number of research firms have commented on VOR. HC Wainwright reissued a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird cut their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a report on Monday, December 9th.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. lifted its stake in Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after acquiring an additional 16,897,159 shares during the period. Lynx1 Capital Management LP acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $707,000. Two Sigma Investments LP lifted its stake in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after acquiring an additional 25,930 shares during the period. Northern Trust Corp lifted its stake in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after acquiring an additional 44,252 shares during the period. Finally, Trustees of Columbia University in the City of New York acquired a new stake in Vor Biopharma during the 4th quarter valued at approximately $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Price Performance

VOR stock opened at $0.88 on Friday. The company has a market capitalization of $60.44 million, a PE ratio of -0.53 and a beta of -0.45. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $2.43. The firm’s 50-day moving average is $1.33 and its 200 day moving average is $1.01.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.